BioSpace News Archive

Texas Biomedical Research Institute’s 3rd Global Health Symposium on May 18 and 19 will convene experts from across the nation and the world to discuss how community, trust and science can help build health equity.

Celyad Oncology received a letter on April 19th, 2023 from The Nasdaq Stock Market informing the Company that the minimum closing bid price per share of its American Depositary Shares representing ordinary shares was below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5450.

Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, announced the appointment of Roger Dansey, M.D., to the company’s Board of Directors.

RxSight, Inc. today announced that its Light Adjustable Lens™ system will be the subject of multiple surgeon presentations at the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) being held at the San Diego Convention Center on May 5-8, 2023.

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2023, after the market close on Monday, May 15, 2023.

Kineta, Inc. announced that it has closed its previously announced registered direct offering for the purchase and sale of 1,425,179 shares of the Company’s common stock at a purchase price of $4.21 per share of common stock priced at-the-market under Nasdaq rules.

Sana Biotechnology, Inc., a company focused on changing the possible for patients through engineered cells, announced that management will host a Research & Development Day on Thursday, May 23, 2023 from 9:00 a.m. – 12:00 p.m. ET in New York, NY.

SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced that the company will be participating in the upcoming 2023 Bank of America Merrill Lynch Global Healthcare Conference in Las Vegas.

LumiraDx Limited announced that it has received notification from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450 for continued listing on the Nasdaq Global Market, since the closing bid price for the Company’s common shares on the Nasdaq Global Market was below US$1.00 for 30 consecutive trading days.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will present data on INBRIJA (levodopa inhalation powder) and OFF Periods at the American Academy of Neurology (AAN) Annual Meeting, taking place in Boston from April 22 to April 27, 2023.